These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 20610171
21. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Holt S, Comelli F, Costa B, Fowler CJ. Br J Pharmacol; 2005 Oct; 146(3):467-76. PubMed ID: 16100529 [Abstract] [Full Text] [Related]
24. Inhibition of fatty-acid amide hydrolyse (FAAH) exerts cognitive improvements in male but not female rats. Hlavacova N, Chmelova M, Danevova V, Csanova A, Jezova D. Endocr Regul; 2015 Jul; 49(3):131-6. PubMed ID: 26238495 [Abstract] [Full Text] [Related]
25. Radiosynthesis and ex vivo evaluation of [(11)C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors. Hicks JW, Parkes J, Tong J, Houle S, Vasdev N, Wilson AA. Nucl Med Biol; 2014 Sep; 41(8):688-94. PubMed ID: 24969632 [Abstract] [Full Text] [Related]
26. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Moreira FA, Kaiser N, Monory K, Lutz B. Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120 [Abstract] [Full Text] [Related]
30. Fatty acid amide hydrolase inhibitor (URB597) as a regulator of myocardial lipid metabolism in spontaneously hypertensive rats. Harasim-Symbor E, Polak A, Pędzińska-Betiuk A, Weresa J, Malinowska B, Lewandowska A, Kasacka I, Chabowski A. Chem Phys Lipids; 2019 Jan; 218():141-148. PubMed ID: 30578756 [Abstract] [Full Text] [Related]
31. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Haller VL, Stevens DL, Welch SP. Eur J Pharmacol; 2008 Dec 14; 600(1-3):50-8. PubMed ID: 18762181 [Abstract] [Full Text] [Related]
33. FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Greco R, Demartini C, Zanaboni AM, Tumelero E, Reggiani A, Misto A, Piomelli D, Tassorelli C. Neurobiol Dis; 2020 Feb 14; 134():104624. PubMed ID: 31629892 [Abstract] [Full Text] [Related]
36. The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Paylor B, Holt S, Fowler CJ. Pharmacol Res; 2006 Dec 14; 54(6):481-5. PubMed ID: 16997568 [Abstract] [Full Text] [Related]
37. Brain uptake and metabolism of the endocannabinoid anandamide labeled in either the arachidonoyl or ethanolamine moiety. Hu K, Sonti S, Glaser ST, Duclos RI, Gatley SJ. Nucl Med Biol; 2017 Feb 14; 45():43-50. PubMed ID: 27889577 [Abstract] [Full Text] [Related]
38. Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers. Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M, Zannikos P, van der Ark P, Palmer JA, Rassnick S, Celen S, Bormans G, van Laere K. Clin Transl Sci; 2018 Jul 14; 11(4):397-404. PubMed ID: 29575526 [Abstract] [Full Text] [Related]
39. The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Thors L, Alajakku K, Fowler CJ. Br J Pharmacol; 2007 Apr 14; 150(7):951-60. PubMed ID: 17325653 [Abstract] [Full Text] [Related]
40. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. Biol Psychiatry; 2007 Nov 15; 62(10):1103-10. PubMed ID: 17511970 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]